focus -WSS

focus

author：entertainment 2025-08-19 18:06:42 - browse：569

Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research within the Food and Drug Administration, at a hearing — policy coverage from STAT — Peter Marks, director of the FDA's Center for Biologics Evaluation and Research Greg Nash/Pool via AP

WASHINGTON — A top Food and Drug Administration official wants Congress to dedicate full-time staff to emerging pathogens, after the FDA scrambled to find people for Covid-19 priorities like Operation Warp Speed.

“Vaccines were a pretty heavy duty lift during the pandemic,” said Peter Marks, director of the Center for Biologics Evaluation and Research, at a Thursday Politico event. “Rather than having to essentially reassign whole groups of people and disrupt things, the idea is to have a group of people who are constantly working on this.”

There is reason for optimism. Sens. John Hickenlooper (D-Colo.) and Ted Budd (R-N.C.) successfully added an amendment creating that team to a key pandemic preparedness bill that must be reauthorized by the end of September. It would establish this new program within Marks’ division of the FDA, staffed with experts on vaccines, antibodies, diagnostic tests, personal protective equipment, and other medical countermeasures. Among other activities, this team would enhance surveillance programs and prioritize vaccine research and development so that existing platforms can be retooled to fight other viruses.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： The future of health care in the House

leisure time

WSS

A virus, fished out of a lake, may have saved a man’s life

Hospitals look to new technology to keep health care workers safe

Hospitals look to new technology to keep health care workers safe

Childhood cancer progress stalls for Black, Hispanic kids: Report

Poor hospice wound care hurts patients and families

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

hotspot

focus

focus

Dobbs anniversary: the lost opportunity of abortion as health care

FDA panel signals lack of confidence in Amgen cancer drug data

Novavax promises a turnaround & Lilly roils the obesity market

When women are denied an abortion, their children fare worse than peers

Medicare details structure of new drug price negotiation program

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Medical records are filled with copy

AI can decode, harness the power of the humane immune system

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Childhood cancer progress stalls for Black, Hispanic kids: Report

knowledge

Sana to lay off nearly a third of staff, de

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Sana to lay off nearly a third of staff, de

Sana to lay off nearly a third of staff, de

Morphosys mixed study results for blood cancer drug

Childhood cancer progress stalls for Black, Hispanic kids: Report

Wikipedia

leisure time

focus

hotspot